Journey Medical Corp DERM
Journey Medical Corp (Nasdaq: DERM) is a dermatology drug developer. Its lead program, Emrosi (minocycline modified-release capsules 40 mg), is marketed for Inflammatory lesions of rosacea in adults.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Emrosi (DFD-29) | Inflammatory lesions of rosacea | small molecule | Approved |
| Qbrexza | Primary axillary hyperhidrosis | small molecule | Approved |
| Accutane | Severe recalcitrant nodular acne | small molecule | Approved |
| Amzeeq / Zilxi (minocycline topical foams) | Acne vulgaris / rosacea | small molecule | Approved |
| Eurax | Dermatology (acquired product, amortization began Q1 2026) | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved dermatology companies
- Evolus, Inc. EOLS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.